What GIP does in Mounjaro — and why it matters

The myth: GIP is just a supporting role to GLP-1

A common assumption is that GLP-1 does the real work in Mounjaro and GIP is a minor add-on. That is not what the evidence shows. For years, GIP was actually considered a poor candidate for weight-loss medicine: early research suggested it might promote fat storage rather than reduce it, and some scientists argued against targeting it. Tirzepatide's developers went in the opposite direction, and the clinical results have since reframed that thinking entirely.

What researchers found is that the effect of activating GIP receptors depends heavily on context, specifically, on what else is happening metabolically at the same time. When GIP and GLP-1 receptors are activated together, as they are by tirzepatide, the combined signalling appears to produce appetite suppression, improved insulin sensitivity and changes in fat metabolism that neither pathway achieves as fully on its own. The interaction between GLP-1 and GIP is the mechanism, not just the sum of two separate effects.

A question our prescribers hear most weeks is whether patients could just take a GLP-1 medicine and "add" GIP on top somehow. They cannot. Tirzepatide is a single engineered molecule designed to bind both receptor types with specific affinity, it is not two medicines combined. That distinction matters for understanding what Mounjaro is and is not.

What GIP receptors actually do, and where they are found

GIP receptors are distributed far more widely than most people expect. Yes, they are found in the pancreatic beta cells where GIP stimulates insulin release after a meal. But they are also present in adipose (fat) tissue, skeletal muscle, bone and the central nervous system, including regions of the brain involved in energy balance and appetite control.

In fat tissue, GIP receptor activation appears to help shift the body towards burning stored fat rather than conserving it, roughly the opposite of what older research had suggested GIP alone might do. In the hypothalamus and other appetite-relevant brain areas, GIP signals interact with the brain's satiety circuits, reducing hunger signals that would otherwise push you to eat more.

Bone is another site worth noting: GIP is thought to play a protective role in bone density, which is one reason researchers monitor bone health across GLP-1 and dual-agonist trials. This does not change the treatment's clinical use for weight management, but it illustrates that GIP's reach in the body is considerably broader than simply "helping with blood sugar".

For a fuller picture of how the individual receptor pathways compare, the science behind tirzepatide's GIP activity covers the mechanistic detail. The NHS's tirzepatide medicine page also describes the dual-receptor action in plain terms, see NHS: tirzepatide.

What the clinical trial data say about the dual mechanism

The SURMOUNT-1 trial (2,539 adults with obesity, followed for 72 weeks) showed average body-weight reductions of around 20–21% at the highest tirzepatide dose, figures that were notably higher than those seen in equivalent semaglutide (GLP-1-only) trials of the same duration. Tirzepatide's overall results profile remains the strongest published for any UK-licensed weight-loss injection.

The more direct comparison came in SURMOUNT-5, an open-label head-to-head trial published in the New England Journal of Medicine in 2025 (751 adults, 72 weeks). Tirzepatide produced greater average weight reduction than semaglutide 2.4mg, the result that most clearly attributes the extra benefit to the presence of the GIP mechanism, since the GLP-1 component is shared between the two medicines.

Researchers are cautious about isolating exactly how much of tirzepatide's effect comes from GIP versus GLP-1, because the dual signalling creates effects that do not map cleanly onto either receptor in isolation. What the trials do confirm is that the combination outperforms GLP-1 alone for average weight loss in this population. If you want to explore the cost side of accessing tirzepatide privately, this page covers UK pricing context honestly. The clinical picture, though, is the better starting point.

NICE's appraisal of tirzepatide (NICE TA1026) referenced the indirect comparisons favouring tirzepatide when recommending it for adults with a BMI of 35 or above and at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Clinical suitability is always assessed individually.

What this means if you are considering Mounjaro

Understanding what GIP does in Mounjaro will not change whether the medicine is right for you, that is a clinical question. But it does explain why tirzepatide is categorised separately from older GLP-1 injections and why comparisons between them are not straightforward. The GIP pathway is not a marketing distinction; it represents a genuinely different pharmacological action that appears to drive meaningfully different outcomes in trials.

If you want to explore whether Mounjaro is suitable for your circumstances, maximising results on treatment also depends on understanding the biology rather than just the dose. The consultation process at our treatment page is where that clinical conversation starts, reviewed by a GPhC-registered prescriber the same day you submit, not by automated software.